Influence of rosiglitazone on peritoneal fibrosis induced by peritoneal dialysate in rats
10.3724/SP.J.1008.2011.00144
- Author:
Qin LIN
1
Author Information
1. Department of Nephrology
- Publication Type:Journal Article
- Keywords:
Peritoneal dialysis;
Peritoneal fibrosis;
Rosiglitazone
- From:
Academic Journal of Second Military Medical University
2011;32(2):144-149
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the effect of rosiglitazone (RGZ) in prevention of peritoneal fibrosis induced by peritoneal dialysis in rats. Methods: Fifty SD rats were randomly divided into six groups: control group (n = 5), normal saline (NS) group(n = 9), model group (n=9), dimethyl sulfoxide(DMSO) group(n = 9), low-dose RGZ group (n = 9), and high-dose RGZ group (n = 9). Peritoneal catheters were implanted in the last five groups, and peritoneal fibrosis models were induced in the last four groups by high-glucose peritoneal dialysate and erythromycin with rats. Animals in the low-dose RGZ and high-dose RGZ groups were treated with 1.5 mg/kg RGZ and 15 mg/kg RGZ, respectively. The one hour peritoneal equilibration test was performed and the plasma glucose and serum lipids were estimated five weeks after dialysis. The ultrafiltration volume (UF), dialysate-to-plasma urea ratio (D/Purea), and glucose reabsorption (D1/D0) were calculated. The visceral peritoneum tissues of rats were stained with hematoxylin-eosin(H-E) and Masson trichrome staining to observe the changes of peritoneal morphology. Blood vessels and leukocytes of peritoneum were quantified as n/mm2 within the histological sections with H-E staining. The expression of TGF-β1 and α-SMA in the parietal peritoneum was detected by immunohistochemistry assay. Results: Compared with the control group, the numbers of peritoneal vessels, leukocytes, peritoneal thickness, and the expressions of TGF-β1 and α-SMA were significantly higher in the model group and DMSO group (P<0.05). Administration of RGZ improved the above changes and significantly decreased the expression of TGF-β1 and α-SMA in the model and DMSO groups (P<0.05). Compared with the control group, the UF and D1/D0 were significantly lower and D/Purea was significantly higher in the rest five groups (P<0.05), and there were no significant differences between the low-dose RGZ group and the high-dose RGZ group(P>0.05). Conclusion: Administration of rosiglitazone can effectively protect the ultrafiltration function of peritoneum during peritoneal dialysis and delay the progression of peritoneal fibrosis.
